April 29th 2025
Jon Giles, MD, speaks to the power of personalized medicine and multidisciplinary care to enhance treatment for patients with rheumatoid arthritis (RA).
Cardiac Radiotherapy May Increase Late Disease Risk in Pediatric Cancer Survivors
August 30th 2023Increasing radiation doses to the whole heart appear to correlate with higher risks of valvular disease, coronary artery disease, and heart failure in childhood cancer survivors, a recent study found.
Read More
More Black vs White Patients Have Risk Factors for LV Hypertrophy
August 30th 2023Investigators conducted this subanalysis among patients aged 20 to 27 years, using data from the National Growth and Health Study to determine potential racial differences in left ventricular mass among female patients with obesity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Study Suggests CAR T-Cell Therapy Safe, Effective After Allo-SCT in Multiple Myeloma
August 26th 2023A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma experience comparable outcomes to allo-SCT–naïve patients.
Read More
Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL
August 23rd 2023Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
Watch
Review: Venetoclax Plus HMAs Offer “Moderate” Benefit in AML/MDS After Relapse Post Transplant
August 22nd 2023There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation.
Read More
Study Validates PSA-Based Recurrence Definitions for Prostate Cancer Prognostication
August 19th 2023Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment failure compared with other PSA-based definitions.
Read More
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma
August 18th 2023The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.
Read More
CAR T-Cell Therapy Shown Safe, Effective in MCL With CNS Involvement
August 18th 2023A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe and effective.
Read More
Laura Wingate Discusses Patient Education for Biosimilar Switches vs New Starts, Interchangeability
August 15th 2023Greater attention needs to be on educating patients who are switching from a reference product they are successful on to a biosimilar than a patient who is starting a treatment with a biosimilar at the beginning of their disease journey, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Watch